Scully, Tiffany
Kase, Nathan
Gallagher, Emily J.
LeRoith, Derek
Funding for this research was provided by:
National Institutes of Health (K08CA190770, R01CA200553)
Article History
Received: 15 September 2020
Accepted: 24 August 2021
First Online: 9 September 2021
Competing interests
: TS and NK declare no competing interests. EJG declares the following competing interests: EJG has served on an advisory board for Novartis Pharmaceuticals and as consultant for Seattle Genetics and SynDevRx. DLR declares the following competing interests: DLR has served on advisory boards for Mannkind and AstraZeneca.